Gynecologic oncology reports
August 12, 2026 · via Europe PMC
Real-world clinical outcomes of Trastuzumab Deruxtecan in HER2-expressing ovarian and endometrial Cancer.
Silverstein J, Alomaja O, Chatram D, +7 more, Konecny GE.
AI summary — for doctors, generated from the abstract only
Real-world trastuzumab deruxtecan in HER2-expressing ovarian and endometrial cancer achieved a 45.9% response rate and median PFS of 6.2 months, with responses increasing with HER2 expression.
What was studied
A single-center retrospective cohort of 40 patients (20 ovarian, 20 endometrial cancer) receiving T-DXd (2022-2026).
Key findings
- Median rwPFS 6.2 months; rwRR 45.9%; DCR 67.6%
- Response by HER2 IHC: 1+ 16.7%, 2+ 39.1%, 3+ 86% (p=0.03)
- Prior PARP inhibitor exposure associated with shorter PFS (HR 4.36)
- Pneumonitis in 10% (one grade 3)
Clinical relevance
These data support T-DXd use in HER2-expressing gynecologic cancers consistent with DESTINY-PanTumor02, with HER2 3+ tumors most likely to respond and monitoring for pneumonitis.
Who should care
Limitations
Small single-center retrospective study.
T-DXd works in real-world HER2-expressing gynecologic cancers, best with high HER2.
This is an AI-generated summary of the published abstract, not a clinical recommendation. It may not reflect the full text or subsequent updates — verify against the original source before acting on it.
Abstract
ObjectiveTrastuzumab deruxtecan (T-DXd), a HER2-directed antibody-drug conjugate, received FDA approval on April 5, 2024 for HER2-expressing solid tumors based on the phase II DESTINY-PanTumor02 trial (n = 40 per tumor type). Despite rapid clinical adoption, real-world evidence in gynecologic cancers remains limited. This study aims to address this gap.MethodsThis single-center retrospective cohort study included patients with ovarian cancer (OC) or endometrial cancer (EC) who received T-DXd between September 2022 and January 2026. Primary outcomes were real-world progression free survival (rwPFS) and real-world response rate (rwRR). Secondary outcomes included real-world disease control rate (rwDCR), safety, and time on treatment (TOT). Exploratory analysis aimed to evaluate predictors of progression or death on T-DXd using multivariate cox regression.ResultsAs of February 2026, 40 patients (20 OC, 20 EC) received T-DXd, with a median follow-up of 23 months. All 40 were analyzed for PFS; 37 were response evaluable. HER2 IHC expression was 12.5% 1+, 62.5% 2+, and 20% 3+. Median rwPFS was 6.2 months (95% CI, 3.3-8.6), with a rwRR of 45.9% and rwDCR of 67.6%. rwRR increased significantly with HER2 expression (1+ 16.7%, 2+ 39.1%, 3+ 86%, p = 0.03). In multivariate analysis, PARP inhibitor exposure was associated with significantly shorter PFS (HR 4.36, p = 0.04). Four patients (10%) developed pneumonitis: three (7.5%) grade 1/2, and one (2.5%) grade 3.
Conclusions
T-DXd demonstrated promising real-world clinical outcomes in OC and EC that mirror DESTINY-PanTumor02. Responses were observed across HER2 IHC expression levels (1+ to 3+), with highest rwRR among HER2 3+. Prior PARP inhibitor exposure was associated with significantly shorter PFS, warranting further exploration.
DOI
10.1016/j.gore.2026.102183
PMID
42621866
PMCID
PMC13487597
Research metadata (titles, abstracts, authors, publication dates) is sourced from Europe PMC, which aggregates content from PubMed/MEDLINE, PubMed Central, and other providers under the U.S. National Library of Medicine (NLM/NCBI). NLM does not claim copyright on abstracts; the original journal publishers or authors may hold rights to the full articles. AI-generated summaries are derived only from the abstract, never the full text, and are always labeled as AI-generated.
Want more like this?
Browse more from the feed. A free account unlocks the full feed, saving and communities.
Back to the research feed